Compare SJ & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SJ | SCYX |
|---|---|---|
| Founded | 2011 | 1999 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.6M | 44.0M |
| IPO Year | 2018 | 2014 |
| Metric | SJ | SCYX |
|---|---|---|
| Price | $0.90 | $4.37 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 68.9K | ★ 94.2K |
| Earning Date | 04-23-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.36 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $257,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $608.78 |
| P/E Ratio | $21.79 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.45 | $0.57 |
| 52 Week High | $1.63 | $5.62 |
| Indicator | SJ | SCYX |
|---|---|---|
| Relative Strength Index (RSI) | 37.79 | 54.29 |
| Support Level | $0.77 | $0.67 |
| Resistance Level | $0.84 | $5.62 |
| Average True Range (ATR) | 0.12 | 0.37 |
| MACD | -0.00 | -0.07 |
| Stochastic Oscillator | 5.80 | 37.01 |
Scienjoy Holding Corp is a provider of mobile live streaming platforms in China and focuses on interactive show live streaming from broadcasters to users. It operates a mobile live streaming business by which it provides live streaming entertainment from professional broadcasters to end-users, allowing for the operation of live social video communities. Using its mobile applications, users can select broadcasters and enter real-time video rooms to interact with them. In addition to the real-time interaction, users can also view photos posted by broadcasters in their personal pages, leave comments, and engage in private chats with broadcasters when such broadcasters are not streaming. In addition, users can also play simple, fun games using virtual currencies within the video rooms.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.